Capstone thesis submitted for undergraduate studies on the utility of genomic surveying tools in improving sudden cardiac arrest risk stratification and prediction of sudden cardiac death.
Precision Medicine in Oncology InformaticsWarren Kibbe
Precision medicine in oncology aims to provide targeted cancer treatments based on a patient's individual tumor characteristics. The presentation discusses precision oncology initiatives including NCI-MATCH clinical trials which assign cancer therapies based on a tumor's molecular abnormalities rather than location. It outlines plans to expand genomically-based cancer trials, understand and overcome treatment resistance through molecular analysis, and establish a national cancer database integrating genomic and clinical data to accelerate cancer research. Cloud computing platforms are being developed to provide researchers access to large cancer genomic and clinical datasets. The goal is to advance precision cancer treatment by incorporating individual patient genetics and biomarkers into therapeutic decision making.
This document discusses precision medicine and its future applications. It notes that currently many patients do not respond to initial treatments for common conditions like depression, asthma, diabetes and Alzheimer's. Precision medicine aims to change this by using massive datasets including genomics, clinical information, and population data to better understand disease at the individual level and tailor diagnosis and treatment specifically for each patient. This more personalized approach could help get the right treatment to patients more quickly and effectively.
Type 1 diabetes and alopecia areata are organ-specific autoimmune diseases sharing a number of striking
similarities. Careful consideration of these may forward the clinical and research goals of both fields.
This document discusses advances in personalized cancer treatment and improving patient quality of life. It outlines goals of anti-cancer therapy including maximizing survival, treating symptoms, and improving quality of life. Studies show quality of life scores can predict survival, and improvements in physical functioning correlate with better outcomes. Targeted and precision therapies are highlighted like treatments for EGFR mutations in lung cancer and BRAF mutations in melanoma. Challenges in developing precision medicines are addressed, but new technologies are making genome sequencing cheaper and more accessible to guide individual treatment.
Natalia Barrera is a medical student studying DNA structure and genes. She discusses three recent studies that could help improve medical treatment and diagnosis. The first study found that analyzing certain genes could distinguish between viral and bacterial infections, helping doctors determine if antibiotics are needed. However, the test currently has only 55% accuracy and takes 4-6 hours for results. The second study identified 172 combinations of tumor suppressor genes and drugs that were effective against human cancer cells, which could provide more treatment options for precision medicine. The third study discusses how improving diagnosis through these new tests could help reduce antibiotic overuse and resistance while giving patients greater treatment options and life expectancy for cancer.
This document summarizes a presentation on genes and environment in personalized medicine. It discusses:
1) How existing databases of gene-disease associations are limited for applying genome sequencing results to an individual patient due to incomplete data.
2) A database called VARIMED that aims to address these limitations by curating over 12,000 papers and 192,000 SNPs and their associations with 4,400 diseases and phenotypes.
3) Challenges in moving from odds ratios to likelihood ratios for assessing disease risk based on genomic data and an individual's clinical information.
The document discusses the Precision Medicine Initiative (PMI) and Cancer Moonshot program. PMI aims to tailor medical treatment to individual characteristics like genes and lifestyle by collecting health data from 1 million volunteers. Cancer Moonshot seeks to accelerate cancer research advances by 5 years through tumor mapping, new technologies, data sharing, and engaging patients. Challenges include genetics not explaining all disease, tumor heterogeneity, and defining success. Precision medicine could reduce ineffective treatments and costs while advancing scientific understanding of disease.
Capstone thesis submitted for undergraduate studies on the utility of genomic surveying tools in improving sudden cardiac arrest risk stratification and prediction of sudden cardiac death.
Precision Medicine in Oncology InformaticsWarren Kibbe
Precision medicine in oncology aims to provide targeted cancer treatments based on a patient's individual tumor characteristics. The presentation discusses precision oncology initiatives including NCI-MATCH clinical trials which assign cancer therapies based on a tumor's molecular abnormalities rather than location. It outlines plans to expand genomically-based cancer trials, understand and overcome treatment resistance through molecular analysis, and establish a national cancer database integrating genomic and clinical data to accelerate cancer research. Cloud computing platforms are being developed to provide researchers access to large cancer genomic and clinical datasets. The goal is to advance precision cancer treatment by incorporating individual patient genetics and biomarkers into therapeutic decision making.
This document discusses precision medicine and its future applications. It notes that currently many patients do not respond to initial treatments for common conditions like depression, asthma, diabetes and Alzheimer's. Precision medicine aims to change this by using massive datasets including genomics, clinical information, and population data to better understand disease at the individual level and tailor diagnosis and treatment specifically for each patient. This more personalized approach could help get the right treatment to patients more quickly and effectively.
Type 1 diabetes and alopecia areata are organ-specific autoimmune diseases sharing a number of striking
similarities. Careful consideration of these may forward the clinical and research goals of both fields.
This document discusses advances in personalized cancer treatment and improving patient quality of life. It outlines goals of anti-cancer therapy including maximizing survival, treating symptoms, and improving quality of life. Studies show quality of life scores can predict survival, and improvements in physical functioning correlate with better outcomes. Targeted and precision therapies are highlighted like treatments for EGFR mutations in lung cancer and BRAF mutations in melanoma. Challenges in developing precision medicines are addressed, but new technologies are making genome sequencing cheaper and more accessible to guide individual treatment.
Natalia Barrera is a medical student studying DNA structure and genes. She discusses three recent studies that could help improve medical treatment and diagnosis. The first study found that analyzing certain genes could distinguish between viral and bacterial infections, helping doctors determine if antibiotics are needed. However, the test currently has only 55% accuracy and takes 4-6 hours for results. The second study identified 172 combinations of tumor suppressor genes and drugs that were effective against human cancer cells, which could provide more treatment options for precision medicine. The third study discusses how improving diagnosis through these new tests could help reduce antibiotic overuse and resistance while giving patients greater treatment options and life expectancy for cancer.
This document summarizes a presentation on genes and environment in personalized medicine. It discusses:
1) How existing databases of gene-disease associations are limited for applying genome sequencing results to an individual patient due to incomplete data.
2) A database called VARIMED that aims to address these limitations by curating over 12,000 papers and 192,000 SNPs and their associations with 4,400 diseases and phenotypes.
3) Challenges in moving from odds ratios to likelihood ratios for assessing disease risk based on genomic data and an individual's clinical information.
The document discusses the Precision Medicine Initiative (PMI) and Cancer Moonshot program. PMI aims to tailor medical treatment to individual characteristics like genes and lifestyle by collecting health data from 1 million volunteers. Cancer Moonshot seeks to accelerate cancer research advances by 5 years through tumor mapping, new technologies, data sharing, and engaging patients. Challenges include genetics not explaining all disease, tumor heterogeneity, and defining success. Precision medicine could reduce ineffective treatments and costs while advancing scientific understanding of disease.
Scientists are researching genetic treatments to prevent disease by applying genetics to medical care and developing new therapies. A recent study found that extracts from axolotl oocytes were able to reactivate tumor suppressor genes in cancer cells and stop cancer growth in breast cancer cells for 60 days by changing epigenetic marks on DNA. However, simply sequencing genes to identify genetic variants does not provide a full picture of human disease, as the impact of variants needs to be determined through functional studies using good experimental models to better understand complex inherited disorders.
SILS 2015 - Connecting Precision Medicine to Precision Wellness Sherbrooke Innopole
By: Joel Dudley, Mount Sinai School of Medicine
At Sherbrooke International Life Sciences Summit - 2nd edition | September 28/29/30 2015
www.sils-sherbrooke.com
The Cochrane Collaboration Colloquium: The Human Genome Epidemiology Network:...Cochrane.Collaboration
The document summarizes the work of the Human Genome Epidemiology Network (HuGENet) which aims to assess the impact of human genetic variation on health and disease through global collaboration. It notes the large number of potential genetic risk factors (over 10 million) based on genes, their combinations and interactions with environmental factors. It also discusses some of the major challenges in human genome epidemiology research including small sample sizes, small genetic effects, and difficulties in replicating findings. HuGENet takes a network approach, establishing various disease-specific consortia and study platforms to facilitate large collaborative studies and harmonization of methods to overcome these challenges.
The document discusses AIDS cure research funding and progress. It finds that AIDS cure research is astonishingly underfunded, with the NIH spending less than 3% of its AIDS budget on cure research in 2009. Meanwhile, treatment and care for AIDS costs billions per year. Two major approaches are being pursued: activating dormant infected cells, and changing people's immune systems through approaches like stem cell transplants. The Berlin Patient case provided proof of concept that stem cell transplants can cure AIDS, but is not practical for most. More funding is needed to translate basic science into treatments and clinical trials.
A slide series to learn and appreciate the importance and the potential of Personalized/Individualized Genomic Medicine. It briefly goes through the idea of biotechnology and the advancements we have made in biology and technology. A series of applications for genomic medicine is then explored, not failing to mention the challenges we have to overcome as well, for the next medical revolution.
A case for personalized medicine is presented.
Computational challenges in precision medicine and genomicsGary Bader
Genomics is mapping complex data about human biology and promises major medical advances. In particular, genomics is enabling precision medicine, the use of a patient's genome and physiological state to improve therapeutic efficacy and outcome. However, routine use of genomics data in medical research is in its infancy, due mainly to the challenges of working with "Big data". These data are so complex and large that typical researchers are not able to cope with them. Collectively, these data require an understanding of many aspects of experimental biology and medicine to correctly process and interpret. Data size is also an issue, as individual researchers may need to handle tens of terabytes (genomes from a few hundred patients), which is challenging to download and store on typical workstations. To effectively support precision medicine, scientists from a wide range of disciplines, including computer science, must develop algorithms to improve precision medicine (e.g. diagnostics and prognostics), genome interpretation, raw data processing and secure high performance computing.
From Bits to Bedside: Translating Big Data into Precision Medicine and Digita...Dexter Hadley
Lecture Objectives:
1) To use examples from my research to define and introduce the ideals of precision medicine and digital health. 2) To introduce how large scale population-wide analysis of data can be used to facilitate these two ideals. 3) To introduce how freely available open data can be used to facilitate these two ideals. 4) To show how mobile technology can be used to facilitate these two ideals.
With recent advances in Healthcare, Personalized medicine has become a buzzword. The customization of health care, based on DNA sequencing, patient's environmental information, can lead to more efficient treatments.
By integrating various sources of data, personalized medicine improves all aspects of healthcare from prevention to monitoring.
Date held: February 12, 2015
Presented by: Deb Davison, Genomic Health
Topics discussed:
The latest in genomic testing and its role in cancer treatment
The most recent results from Genomic Health’s second independent clinical validation study of Oncotype DX® in DCIS patients
Q&A session about the implications of this research
Precision Medicine in Oncology InformaticsWarren Kibbe
This document summarizes a presentation on precision medicine in oncology from an informatics perspective. It discusses the goals of precision oncology to target cancer treatments based on a patient's individual tumor characteristics. Major initiatives are described, including the NCI-MATCH trial which assigns cancer therapies based on a tumor's molecular abnormalities. The presentation outlines efforts through the Precision Medicine Initiative to expand genomic cancer trials, understand and overcome resistance to therapies through additional tumor profiling and preclinical models, and establish an integrated national cancer database.
This document summarizes a presentation on new sources of big data for precision medicine. It discusses how new data sources like genomics, the human microbiome, epigenomics, and the exposome are generating large amounts of data. It then covers the evolution of precision medicine from concepts like personalized medicine and how strategic initiatives in the UK and US are supporting precision medicine research through funding programs and projects like the Cancer Genome Atlas, eMERGE, and exposome studies. The presentation raises the question of whether we are ready for precision medicine given these new data sources and research efforts.
This document summarizes several research articles on medical genetics. It discusses findings that thousands of genes can influence most diseases through tiny contributions, rather than a few major genes. It also describes a new method using RNA sequencing to diagnose genetic disorders by revealing errors in DNA execution and identifying candidate genes. The student believes further investigating gene networks and non-coding regions will be important for understanding rare conditions and developing treatments.
This document describes the principles, organization, and operation of a DNA bank established by the Department of Veterans Affairs Cooperative Studies Program. The DNA bank was created to facilitate genetic research using DNA samples collected from participants in clinical trials and studies. Key aspects discussed include obtaining informed consent from participants, ensuring privacy and confidentiality, resolving issues around ownership and future use of genetic material, and providing an infrastructure to support linking genetic and clinical data. The DNA bank is intended to be a shared resource that can support future genetic research across multiple clinical studies in different disease areas over time.
MT115 Precision Medicine: Integrating genomics to enable better patient outcomesDell EMC World
"The emergence of genomics and real-time screening is helping to transform the practice of medicine as we know it today. New technologies present improved ways to tackle health issues and what was once thought to be “untouchable” due to cost, timing or resources, is now achievable through genetic screenings and genome sequencing.
During this session, we will explore:
1. The benefits of incorporating a genomics strategy early in lifeline
2. The Precision Medicine Initiative – how does this help? Does this encourage more people to get genetic screenings?
3. What’s involved in a genetic screening
"
Please share this webinar with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
Cancer care is increasingly tailored to individual patients, who can undergo genetic or biomarker testing soon after diagnosis, to determine which treatments have the best chance of shrinking or eliminating tumours.
In this webinar, a pathologist and clinical oncologist discuss:
● how they are using these new tests,
● how they communicate results and treatment options to patients and caregivers, and
● how patients can be better informed on the kinds of tests that are in development or in use across Canada
View the video: https://youtu.be/_Wai_uMQKEQ
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Genetics is becoming more personalized with direct-to-consumer genetic testing services like 23andMe. 23andMe analyzes customers' DNA samples and provides information about their ancestry, traits, and disease risks through an online platform. This empowers individuals and facilitates research by creating a large participant network. While challenges remain in fully engaging all stakeholders, personalized genetics has the potential to transform healthcare by better targeting treatment to individual genetics.
Prostate cancer is the most prevalent and second cause of death from cancer in
men worldwide. Immunotherapy is a new method for the treatment of several cancers
that fights cancer cells by strengthening the immune system through some medications.
While immunotherapy is a useful method for cancer treatment; its’ side effects still are
not totally clarified. Numbers of prostate cancer patients which take immunotherapy are
experiencing prostate inflammation and prostatitis after treatment period.
Enterococcus faecalis is Gram-positive and catalase-negative cocci that are common
in the intestines of humans and other animals and cause most enterococcal infections such as intestinal
infections, prostatitis, gastroenteritis and endocarditic. Present study aimed to evaluate the mRNA level of virulence genes which are involved in Enterococcus faecalis pathogenesis in prostate cancer patients that treated by immunotherapy. Expression level of gelatinase E (gelE) and Enterococcal surface protein (
esp genes were examined by Real time PCR in three groups of 68 male subjects. Group A normal subjects, group B prostate cancer patients before start treatment and group C prostate cancer patients after six months immunotherapy period.
Genetic testing for breast cancer like HER2 and gene expression profiling (GEP) can impact healthcare disparities. While HER2 testing is widely used with trastuzumab treatment, there is still some underuse. GEP testing is only modestly used and is associated with less chemotherapy for low risk patients but more for high risk. Studies show black women may be less eligible for GEP and there is inadequate data on effectiveness in diverse groups. Ensuring validation in diverse populations, broad recruitment, and addressing social factors can help reduce disparities in precision medicine.
This document discusses developing a "cardiac moonshot" initiative using precision medicine approaches to more effectively treat heart disease. It outlines how precision medicine considers individual genetic and lifestyle factors. The initiative would leverage technologies like remote monitoring, wearables, and electronic health records to integrate diverse health data. This would allow more personalized treatment and risk prediction. Challenges include standardizing large data collection and educating medical professionals on complex multi-omic data analysis.
This document provides information from GrassrootsHealth on vitamin D research and dosing recommendations. It includes the following:
- A summary of studies showing reductions in disease incidence as vitamin D levels increase from 25 to over 60 ng/ml. Many diseases such as cancer, diabetes and heart disease showed reductions of over 30% at levels of 40 ng/ml or higher.
- Charts showing the wide range of serum vitamin D levels achieved at different daily supplemental intake amounts, based on data from over 7,000 participants. Intakes of 4000 IU/day resulted in levels from 20-120 ng/ml, demonstrating individual variability.
- Recommendations that total daily vitamin D intake of around 12,000 IU
Scientists are researching genetic treatments to prevent disease by applying genetics to medical care and developing new therapies. A recent study found that extracts from axolotl oocytes were able to reactivate tumor suppressor genes in cancer cells and stop cancer growth in breast cancer cells for 60 days by changing epigenetic marks on DNA. However, simply sequencing genes to identify genetic variants does not provide a full picture of human disease, as the impact of variants needs to be determined through functional studies using good experimental models to better understand complex inherited disorders.
SILS 2015 - Connecting Precision Medicine to Precision Wellness Sherbrooke Innopole
By: Joel Dudley, Mount Sinai School of Medicine
At Sherbrooke International Life Sciences Summit - 2nd edition | September 28/29/30 2015
www.sils-sherbrooke.com
The Cochrane Collaboration Colloquium: The Human Genome Epidemiology Network:...Cochrane.Collaboration
The document summarizes the work of the Human Genome Epidemiology Network (HuGENet) which aims to assess the impact of human genetic variation on health and disease through global collaboration. It notes the large number of potential genetic risk factors (over 10 million) based on genes, their combinations and interactions with environmental factors. It also discusses some of the major challenges in human genome epidemiology research including small sample sizes, small genetic effects, and difficulties in replicating findings. HuGENet takes a network approach, establishing various disease-specific consortia and study platforms to facilitate large collaborative studies and harmonization of methods to overcome these challenges.
The document discusses AIDS cure research funding and progress. It finds that AIDS cure research is astonishingly underfunded, with the NIH spending less than 3% of its AIDS budget on cure research in 2009. Meanwhile, treatment and care for AIDS costs billions per year. Two major approaches are being pursued: activating dormant infected cells, and changing people's immune systems through approaches like stem cell transplants. The Berlin Patient case provided proof of concept that stem cell transplants can cure AIDS, but is not practical for most. More funding is needed to translate basic science into treatments and clinical trials.
A slide series to learn and appreciate the importance and the potential of Personalized/Individualized Genomic Medicine. It briefly goes through the idea of biotechnology and the advancements we have made in biology and technology. A series of applications for genomic medicine is then explored, not failing to mention the challenges we have to overcome as well, for the next medical revolution.
A case for personalized medicine is presented.
Computational challenges in precision medicine and genomicsGary Bader
Genomics is mapping complex data about human biology and promises major medical advances. In particular, genomics is enabling precision medicine, the use of a patient's genome and physiological state to improve therapeutic efficacy and outcome. However, routine use of genomics data in medical research is in its infancy, due mainly to the challenges of working with "Big data". These data are so complex and large that typical researchers are not able to cope with them. Collectively, these data require an understanding of many aspects of experimental biology and medicine to correctly process and interpret. Data size is also an issue, as individual researchers may need to handle tens of terabytes (genomes from a few hundred patients), which is challenging to download and store on typical workstations. To effectively support precision medicine, scientists from a wide range of disciplines, including computer science, must develop algorithms to improve precision medicine (e.g. diagnostics and prognostics), genome interpretation, raw data processing and secure high performance computing.
From Bits to Bedside: Translating Big Data into Precision Medicine and Digita...Dexter Hadley
Lecture Objectives:
1) To use examples from my research to define and introduce the ideals of precision medicine and digital health. 2) To introduce how large scale population-wide analysis of data can be used to facilitate these two ideals. 3) To introduce how freely available open data can be used to facilitate these two ideals. 4) To show how mobile technology can be used to facilitate these two ideals.
With recent advances in Healthcare, Personalized medicine has become a buzzword. The customization of health care, based on DNA sequencing, patient's environmental information, can lead to more efficient treatments.
By integrating various sources of data, personalized medicine improves all aspects of healthcare from prevention to monitoring.
Date held: February 12, 2015
Presented by: Deb Davison, Genomic Health
Topics discussed:
The latest in genomic testing and its role in cancer treatment
The most recent results from Genomic Health’s second independent clinical validation study of Oncotype DX® in DCIS patients
Q&A session about the implications of this research
Precision Medicine in Oncology InformaticsWarren Kibbe
This document summarizes a presentation on precision medicine in oncology from an informatics perspective. It discusses the goals of precision oncology to target cancer treatments based on a patient's individual tumor characteristics. Major initiatives are described, including the NCI-MATCH trial which assigns cancer therapies based on a tumor's molecular abnormalities. The presentation outlines efforts through the Precision Medicine Initiative to expand genomic cancer trials, understand and overcome resistance to therapies through additional tumor profiling and preclinical models, and establish an integrated national cancer database.
This document summarizes a presentation on new sources of big data for precision medicine. It discusses how new data sources like genomics, the human microbiome, epigenomics, and the exposome are generating large amounts of data. It then covers the evolution of precision medicine from concepts like personalized medicine and how strategic initiatives in the UK and US are supporting precision medicine research through funding programs and projects like the Cancer Genome Atlas, eMERGE, and exposome studies. The presentation raises the question of whether we are ready for precision medicine given these new data sources and research efforts.
This document summarizes several research articles on medical genetics. It discusses findings that thousands of genes can influence most diseases through tiny contributions, rather than a few major genes. It also describes a new method using RNA sequencing to diagnose genetic disorders by revealing errors in DNA execution and identifying candidate genes. The student believes further investigating gene networks and non-coding regions will be important for understanding rare conditions and developing treatments.
This document describes the principles, organization, and operation of a DNA bank established by the Department of Veterans Affairs Cooperative Studies Program. The DNA bank was created to facilitate genetic research using DNA samples collected from participants in clinical trials and studies. Key aspects discussed include obtaining informed consent from participants, ensuring privacy and confidentiality, resolving issues around ownership and future use of genetic material, and providing an infrastructure to support linking genetic and clinical data. The DNA bank is intended to be a shared resource that can support future genetic research across multiple clinical studies in different disease areas over time.
MT115 Precision Medicine: Integrating genomics to enable better patient outcomesDell EMC World
"The emergence of genomics and real-time screening is helping to transform the practice of medicine as we know it today. New technologies present improved ways to tackle health issues and what was once thought to be “untouchable” due to cost, timing or resources, is now achievable through genetic screenings and genome sequencing.
During this session, we will explore:
1. The benefits of incorporating a genomics strategy early in lifeline
2. The Precision Medicine Initiative – how does this help? Does this encourage more people to get genetic screenings?
3. What’s involved in a genetic screening
"
Please share this webinar with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
Cancer care is increasingly tailored to individual patients, who can undergo genetic or biomarker testing soon after diagnosis, to determine which treatments have the best chance of shrinking or eliminating tumours.
In this webinar, a pathologist and clinical oncologist discuss:
● how they are using these new tests,
● how they communicate results and treatment options to patients and caregivers, and
● how patients can be better informed on the kinds of tests that are in development or in use across Canada
View the video: https://youtu.be/_Wai_uMQKEQ
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Genetics is becoming more personalized with direct-to-consumer genetic testing services like 23andMe. 23andMe analyzes customers' DNA samples and provides information about their ancestry, traits, and disease risks through an online platform. This empowers individuals and facilitates research by creating a large participant network. While challenges remain in fully engaging all stakeholders, personalized genetics has the potential to transform healthcare by better targeting treatment to individual genetics.
Prostate cancer is the most prevalent and second cause of death from cancer in
men worldwide. Immunotherapy is a new method for the treatment of several cancers
that fights cancer cells by strengthening the immune system through some medications.
While immunotherapy is a useful method for cancer treatment; its’ side effects still are
not totally clarified. Numbers of prostate cancer patients which take immunotherapy are
experiencing prostate inflammation and prostatitis after treatment period.
Enterococcus faecalis is Gram-positive and catalase-negative cocci that are common
in the intestines of humans and other animals and cause most enterococcal infections such as intestinal
infections, prostatitis, gastroenteritis and endocarditic. Present study aimed to evaluate the mRNA level of virulence genes which are involved in Enterococcus faecalis pathogenesis in prostate cancer patients that treated by immunotherapy. Expression level of gelatinase E (gelE) and Enterococcal surface protein (
esp genes were examined by Real time PCR in three groups of 68 male subjects. Group A normal subjects, group B prostate cancer patients before start treatment and group C prostate cancer patients after six months immunotherapy period.
Genetic testing for breast cancer like HER2 and gene expression profiling (GEP) can impact healthcare disparities. While HER2 testing is widely used with trastuzumab treatment, there is still some underuse. GEP testing is only modestly used and is associated with less chemotherapy for low risk patients but more for high risk. Studies show black women may be less eligible for GEP and there is inadequate data on effectiveness in diverse groups. Ensuring validation in diverse populations, broad recruitment, and addressing social factors can help reduce disparities in precision medicine.
This document discusses developing a "cardiac moonshot" initiative using precision medicine approaches to more effectively treat heart disease. It outlines how precision medicine considers individual genetic and lifestyle factors. The initiative would leverage technologies like remote monitoring, wearables, and electronic health records to integrate diverse health data. This would allow more personalized treatment and risk prediction. Challenges include standardizing large data collection and educating medical professionals on complex multi-omic data analysis.
This document provides information from GrassrootsHealth on vitamin D research and dosing recommendations. It includes the following:
- A summary of studies showing reductions in disease incidence as vitamin D levels increase from 25 to over 60 ng/ml. Many diseases such as cancer, diabetes and heart disease showed reductions of over 30% at levels of 40 ng/ml or higher.
- Charts showing the wide range of serum vitamin D levels achieved at different daily supplemental intake amounts, based on data from over 7,000 participants. Intakes of 4000 IU/day resulted in levels from 20-120 ng/ml, demonstrating individual variability.
- Recommendations that total daily vitamin D intake of around 12,000 IU
This document discusses the importance of NIH clinical research. It notes that clinical research involves medical studies with human participants and is essential for public health, driving medical discoveries, and reducing disease burden. The document encourages raising awareness of clinical research opportunities by educating the public and physicians, as many trials struggle to find enough participants due to a lack of awareness. Health care providers are seen as key to increasing participation, as patients are more likely to enroll if their doctor recommends it and answers their questions. The NIH website is provided as a resource to promote clinical research.
Consumer and Connected Health: A New Day in Health and Healthcare?Bradford Hesse
Two competing worldviews, the mechanistic and humanistic, are leading to errors in healthcare. The mechanistic view focuses on technologies while the humanistic view focuses on people. The Institute of Medicine calls for a sociotechnical system that considers both. New decision architectures are needed that incorporate patients, providers, and data to improve quality of care.
Jay Cross, a 63-year-old man with a history of heart attacks and other health issues, pays $999 to have his genome sequenced by 23andMe. He is curious about whether his health problems are due to genetics or lifestyle. The results show he has a 20% lower risk of heart attack than average but provide little other useful information. Critics argue direct-to-consumer genetic testing currently offers limited health value given the complexity of gene-disease relationships and lack of expert guidance on interpreting results. As the science progresses, genetic testing may one day provide clearer insights but also raises concerns about overreaction to risk information.
Big Data and the Promise and Pitfalls when Applied to Disease Prevention and ...Philip Bourne
Big data and data science have implications for healthcare and biomedical research. Large amounts of data are being generated but much of it remains unused. Integrating data through common standards could provide new insights into rare diseases. The National Institutes of Health is working to establish data standards and cloud resources to enable data sharing and advance precision medicine through its Precision Medicine Initiative. Data science has the potential to improve disease prevention and health promotion by identifying patterns in large, diverse datasets.
2013-04-17: The Promise, Current State, And Future of Personalized MedicineBaltimore Lean Startup
Jeffrey M. Otto discusses the promise, current state, and future of personalized medicine in a presentation. He begins with definitions of key terms like personalized medicine and biomarkers. He then reviews the early promises of personalized medicine in improving diagnoses, drug development, and treatment effectiveness. However, he notes the field has faced challenges in fully achieving these promises. Currently, the Center for Translational Research is taking an integrated approach using electronic health records, biospecimen samples, and statistical analysis to develop predictive signatures to advance personalized medicine. Their goal is to translate scientific discoveries into clinical applications to improve patient outcomes.
This document provides information from the GrassrootsHealth organization regarding vitamin D research and recommendations. It includes the following:
- A summary of several studies showing reductions in disease incidence as vitamin D serum levels increase from 25 ng/ml to higher levels such as 40-60 ng/ml. Diseases such as cancer, diabetes, fractures, and multiple sclerosis showed reductions.
- Charts analyzing data from over 7,000 participants in the GrassrootsHealth D*action project, showing a wide range of serum levels for any given supplemental vitamin D intake amount. Intakes of 4,000 IU/day resulted in serum levels from 10-150 ng/ml.
- Analysis suggesting supplemental intakes of 9,
The A3BC, Biobanks and the future of precision medicine - A3BC -
Professor Lyn March AM and Craig WIllers discuss The Australian Arthritis and Autoimmune Biobank Collaborative (A3BC), their vision for Autoimmune disease and the future of treatments, medical advances and ultimately a cure for the debilitating group of musculoskeletal diseases.
Emerging Technologies and Tools in Precision Medicine ResearchClinosolIndia
Precision medicine has witnessed significant advancements with the integration of emerging technologies and innovative tools. This abstract explores the current landscape of precision medicine research, focusing on the role of cutting-edge technologies and tools in revolutionizing healthcare approaches.
This document provides information about the "BioData World West 2017" conference taking place April 26-27, 2017 in San Francisco. The conference will bring together over 200 participants from various backgrounds to discuss disruptive approaches in drug development, personalized medicine, and clinical applications using big data in precision medicine. Expert speakers will present on topics including genomics, precision medicine, and a new AI track in partnership with Merck. Registering online reserves a place at the conference and featured sessions will explore various applications and challenges of harnessing big data in healthcare and biomedicine.
This document is an undergraduate thesis that examines the pharmaceutical industry and alternative medicine. It argues that while Western medicine has improved health outcomes for some acute illnesses, the over-reliance on drugs has significant downsides. Preventable medical errors are the third leading cause of death in the US, with pharmaceutical companies more focused on profits than patient safety. The document also suggests that several holistic doctors working on alternative cancer treatments may have been murdered to protect the financial interests of the pharmaceutical industry.
This document outlines a public health approach for realizing the promises of genomics and big data while addressing the challenges. It recommends: 1) Using a strong epidemiological foundation to study disease distribution and determinants in populations. 2) Developing a robust knowledge integration process to synthesize findings from different sources and disciplines. 3) Applying principles of evidence-based medicine and population screening to evaluate genomic applications. 4) Developing a robust translational research agenda beyond clinical applications to improve population health impact. The public health framework can help maximize the benefits of genomics and big data while minimizing risks.
The document discusses personalized medicine and the company 23andMe. It provides definitions of personalized medicine from various sources emphasizing using genetic information to prevent and treat disease. It outlines the history of genomics projects like the Human Genome Project and HapMap. 23andMe allows customers to learn about their genetics through direct-to-consumer genetic testing. Customers submit a saliva sample and access results online regarding ancestry, traits, and disease risks. 23andMe aims to empower individuals and facilitate research through participant-driven studies. The document discusses examples of genetic insights into conditions like cancer and how pharmacogenetics can guide treatment choices.
Revolutionizing Healthcare The Biomedical Industry's Quest for InnovationAustin Seal
The document provides a comprehensive overview of the biomedical industry, examining its history, current challenges, and promising future developments. It traces the roots of biomedicine back to ancient civilizations and explores key milestones like the Renaissance period and modern discoveries of germ theory and antibiotics. Current challenges include navigating regulatory hurdles, addressing ethical dilemmas, and improving global healthcare access. Exciting areas of innovation discussed are precision medicine, regenerative medicine, artificial intelligence, 3D printing, and telemedicine. The future holds possibilities such as artificial organs and neurotechnology breakthroughs, though developing ethical frameworks and global collaboration will be important to ensure responsible progress.
This document discusses varicella zoster virus (VZV) which causes chickenpox and shingles. It provides statistics on the incidence of chickenpox pre- and post-vaccine era in the US. It also discusses risk factors for shingles and strategies to reduce its incidence including exposure to children with chickenpox and the shingles vaccine.
Presentation "The Impact of All Data on Healthcare"
Keith Perry
Associate VP & Deputy CIO
UT MD Anderson Cancer Center
With continuing advancement in both technology and medicine, the drive is on to make all data meaningful to drive medical discovery and create actionable outcomes. With tools and capabilities to capture more data than ever before, the challenge becomes linking existing structured and unstructured clinical data with genomic data to increase the industry’s analytical footprint.
Learning Objectives:
∙ Discuss the need to make all data meaningful in order to speed discovery of new knowledge
∙ Provide examples of an analytical direction that supports evolution in medicine
∙ Expose the challenges facing the industry with respect to ~omits
Morphologomics - Challenges for Surgical Pathology in the Genomic Age by Dr. ...Cirdan
This presentation introduces and discussesthe concept of ‘morphologomics’ that is omics approaches critically reimagined and reappraised from the viewpoint of classic morphology.
It was delivered by Dr. Anthony Gill at the Pathology Horizons 2017 conference in Cairns, Australia.
introduce and discuss the concept of ‘morphologomics’ that is omics approaches critically reimagined and reappraised from the viewpoint of classic morphology.
FasterCures Presentation: Fostering innovation while delivering treatments an...TRAIN Central Station
FasterCures' Margaret Anderson presents at the 2009 BioEconomy Summit Healthcare Policy Session 2: Affordability and Access. Presents new business models to accelerate research.
Similar to International Biobanking: Oportunities and Challenges for Private-Public Collaboration (20)
The document discusses biobanking and the patient perspective from the United States. It notes that while there have been discussions around single vs. tiered consent forms for biospecimen donation, a universal action plan is needed. Patients want confidence that their donated biospecimens will be appropriately shared to advance research.
This document summarizes the preliminary results of a stakeholder forum evaluating the Biobanking and BioMolecular resources Research Infrastructure (BBMRI). It analyzes 10 case studies of existing biobanks and finds that most are 5-7 years old and organized nationally. While collections vary greatly in size, there is a trend toward larger international networks. Funding models are mixed but indicate biobanking requires long-term investment and networking can reduce costs. A social network analysis found the core BBMRI members had a central role in previous EU projects, and more institutions should be included to expand the network.
The document discusses challenges and opportunities around patient involvement in clinical research and biobanking. It describes the objectives and activities of the PatientPartner project, which aims to identify patient needs, facilitate dialogue between stakeholders, and develop strategies to better integrate patient perspectives. The project finds that while full participation models vary, there is agreement on involving patients and a need for basic training, resources, and addressing public perceptions of clinical research.
This document outlines a study evaluating the socio-economic impacts of biobank networking projects. Preliminary results from interviews with members of six biobank networks show several effects, including networking and knowledge transfer. Key factors for generating effects include the size and maturity of biobanks and networks. The study aims to inform evaluation of BBMRI by distinguishing effects of biobanks versus networking and quantifying direct versus indirect impacts, though challenges remain around sampling, attribution and complexity.
WP6 of the BBMRI project aims to design an ethical, legal and social framework for establishing BBMRI. It will propose strategies and scenarios through a series of deliverables including reports on ethics policies in BBMRI countries and documents providing recommendations on harmonization and addressing social dimensions. The work package will develop a conceptual model of governance and an operational governance model to guide BBMRI interactions with stakeholders.
The document discusses the concept of BBMRI Expert Centres, which are proposed as a new public-private partnership model to improve the use of biospecimens for research. The expert centres would provide specialized medical and scientific expertise, standardized analysis platforms, and quality management to facilitate data sharing between academia and industry. This model offers industry access to expertise and reduces sample shipping needs, while avoiding issues around commercialization of samples.
This document summarizes 40 years of research on hemophilia in the Netherlands. It describes the history of hemophilia research starting in 1972 with a student project. Over the decades, surveys were conducted in 1972, 1978, 1985, 1992, and 2001 that involved thousands of hemophilia patients. The surveys tracked changes in treatment, hospital admissions, bleeding events, and life expectancy over time. Research also examined issues like HIV, hepatitis C, genetic counseling, and quality of life. Future research plans include stronger links between survey data and hospital records, and possible cooperation on a biobank.
Fair Access: a practical approach to policy on access for European biobankingBBMRI Stakeholder's Forum
This document summarizes a presentation on fair access policies for biobanks. It discusses defining access narrowly to allow only scientific use of samples, or broadly to optimize research through collaboration with all stakeholders. Fair access should consider donors, collectors, researchers, biobanks, and legal entities. A practical policy frames access through collaboration to assess sample quality and suitability for a given study. Citizen scientist projects can help engage the public and enable new types of research.
The document summarizes the European Research Infrastructure for Biobanking and Biomolecular Resources (BBMRI) preparatory phase project. It discusses how biobanks across Europe have historically been small and fragmented. The BBMRI aims to integrate these resources to enable large-scale biomedical research by establishing common standards and open access. Over 50 institutions from 28 countries are involved in the preparatory phase to develop a prototype pan-European research infrastructure network for biobanking and biomolecular resources.
Disease-related biobanks collect human biological samples and associated clinical data from patients to study the causes and outcomes of diseases. These biobanks vary in their sample sizes and types, levels of institutional support, and whether samples and data are collected and stored according to standard procedures. The document provides examples of disease-related biobanks in Europe and North America that have contributed samples to genome-wide association studies, with the total number of samples collected in Europe significantly higher than in North America. It notes that the BBMRI catalogue seeks to provide an overview of disease-related biobanks.
The Wales Cancer Bank aims to establish a collection of tissue and blood samples from cancer patients in Wales to help identify novel biomarkers for cancer prediction, prognosis, and personalized treatment. It has consented over 3,190 patients from 7 hospitals since 2005. Patients have been actively involved as advisors, donors, and advocates. They provide a unique perspective and want to help advance cancer research that could benefit future patients. The biobank must responsibly use samples for high-quality reproducible research to further knowledge and develop new treatments.
The document summarizes the European Research Infrastructure for Biobanking and Biomolecular Resources (BBMRI) preparatory phase project. It discusses how biobanks across Europe have historically been small and fragmented. The BBMRI aims to integrate these resources to enable large-scale biomedical research. Over 50 institutions from 28 countries are involved in developing common standards, data sharing agreements, and a sustainable funding model to maximize the research potential of Europe's biological samples and data.
The document discusses using a hub and spoke model to connect biobanks in Europe. Key points:
- A hub and spoke structure will be used with federated databases where hubs provide database services and routing of queries at central access points.
- Hubs can focus on different data types like genotypes, phenotypes, samples, or metadata.
- A common schema will allow different national hubs to connect.
- Work package 5 aims to develop standards for identifiers, communication between biobanks, and a shared lexicon/terminology.
- Challenges include changing data definitions, integration of different data types, and dealing with natural language differences between countries.
The document summarizes the European Research Infrastructure for Biobanking and Biomolecular Resources (BBMRI) preparatory phase project. It discusses how biobanks across Europe have historically been small and heterogeneous, hindering modern genetic research. The BBMRI aims to integrate existing biobanks and resources to create a large pan-European infrastructure following common standards. The preparatory phase involved over 50 institutions from 28 countries to assess resources and technologies and develop plans for a sustainable infrastructure to support research.
The document discusses the mission of Work Package 2 (WP2) of BBMRI, which is to provide a strategy to address the legal, governance, and financial challenges of utilizing large epidemiological sample collections and population cohorts. European investigators have collected population-based cohorts and health data over decades using public funds. BBMRI aims to harmonize data across biobanks to facilitate global comparisons. The document also reviews technical solutions and quality criteria for storage, retrieval, and transfer of DNA samples across five biobanks to demonstrate challenges in studying obesity as a model phenotype.
The document discusses the ethical, legal and social issues (ELSI) surrounding biobanks and BBMRI, a European research infrastructure for biobanks and biomolecular resources. It notes that while the founding father of biobanking Antoni van Leeuwenhoek did not consider ELSI, they are important today given concerns about potential misuse of data and the need for public trust and support. The document outlines work being done in BBMRI to address ELSI, including analyzing focus group research on public attitudes, developing legal guidelines and templates through a wiki platform, and considering issues around consent, data sharing and privacy.
The document summarizes the European Research Infrastructure for Biobanking and Biomolecular Resources (BBMRI) which aims to integrate existing biobanks and resources across Europe. It discusses the challenges of harmonizing processes and legal/ethical standards. An inventory of existing biobanks has been conducted. A prototype infrastructure is being developed and legal structure as a European Research Infrastructure Consortium is proposed. The BBMRI aims to foster excellence in biomedical research and be a strategic partner for academia, industry, and the public.
The document discusses collaboration in biobanking to support pharmaceutical R&D activities. It notes that R&D costs are high and innovation is needed. Biobanks can help by providing samples for research into diseases. The document describes AstraZeneca's global biobank network and examples of collaborations on disease-specific biobanks for conditions like rheumatoid arthritis and COPD. It argues that more collaboration is needed through standards, infrastructure, addressing ethical issues, and meeting customer needs to sustain R&D activities.
The document discusses European Union actions to support research infrastructures like biobanks. It outlines the establishment of the European Strategy Forum on Research Infrastructures (ESFRI) to develop a long-term vision and policy for research infrastructures. ESFRI's roadmap identified 44 potential projects, including BBMRI, a pan-European biobank infrastructure. The EU provided funding to develop BBMRI and established a legal framework to facilitate multi-country research infrastructures. Future EU funding calls aim to support the construction and operation of infrastructures like BBMRI to enable collaborative research across Europe.
Full-RAG: A modern architecture for hyper-personalizationZilliz
Mike Del Balso, CEO & Co-Founder at Tecton, presents "Full RAG," a novel approach to AI recommendation systems, aiming to push beyond the limitations of traditional models through a deep integration of contextual insights and real-time data, leveraging the Retrieval-Augmented Generation architecture. This talk will outline Full RAG's potential to significantly enhance personalization, address engineering challenges such as data management and model training, and introduce data enrichment with reranking as a key solution. Attendees will gain crucial insights into the importance of hyperpersonalization in AI, the capabilities of Full RAG for advanced personalization, and strategies for managing complex data integrations for deploying cutting-edge AI solutions.
Have you ever been confused by the myriad of choices offered by AWS for hosting a website or an API?
Lambda, Elastic Beanstalk, Lightsail, Amplify, S3 (and more!) can each host websites + APIs. But which one should we choose?
Which one is cheapest? Which one is fastest? Which one will scale to meet our needs?
Join me in this session as we dive into each AWS hosting service to determine which one is best for your scenario and explain why!
Unlock the Future of Search with MongoDB Atlas_ Vector Search Unleashed.pdfMalak Abu Hammad
Discover how MongoDB Atlas and vector search technology can revolutionize your application's search capabilities. This comprehensive presentation covers:
* What is Vector Search?
* Importance and benefits of vector search
* Practical use cases across various industries
* Step-by-step implementation guide
* Live demos with code snippets
* Enhancing LLM capabilities with vector search
* Best practices and optimization strategies
Perfect for developers, AI enthusiasts, and tech leaders. Learn how to leverage MongoDB Atlas to deliver highly relevant, context-aware search results, transforming your data retrieval process. Stay ahead in tech innovation and maximize the potential of your applications.
#MongoDB #VectorSearch #AI #SemanticSearch #TechInnovation #DataScience #LLM #MachineLearning #SearchTechnology
Best 20 SEO Techniques To Improve Website Visibility In SERPPixlogix Infotech
Boost your website's visibility with proven SEO techniques! Our latest blog dives into essential strategies to enhance your online presence, increase traffic, and rank higher on search engines. From keyword optimization to quality content creation, learn how to make your site stand out in the crowded digital landscape. Discover actionable tips and expert insights to elevate your SEO game.
HCL Notes and Domino License Cost Reduction in the World of DLAUpanagenda
Webinar Recording: https://www.panagenda.com/webinars/hcl-notes-and-domino-license-cost-reduction-in-the-world-of-dlau/
The introduction of DLAU and the CCB & CCX licensing model caused quite a stir in the HCL community. As a Notes and Domino customer, you may have faced challenges with unexpected user counts and license costs. You probably have questions on how this new licensing approach works and how to benefit from it. Most importantly, you likely have budget constraints and want to save money where possible. Don’t worry, we can help with all of this!
We’ll show you how to fix common misconfigurations that cause higher-than-expected user counts, and how to identify accounts which you can deactivate to save money. There are also frequent patterns that can cause unnecessary cost, like using a person document instead of a mail-in for shared mailboxes. We’ll provide examples and solutions for those as well. And naturally we’ll explain the new licensing model.
Join HCL Ambassador Marc Thomas in this webinar with a special guest appearance from Franz Walder. It will give you the tools and know-how to stay on top of what is going on with Domino licensing. You will be able lower your cost through an optimized configuration and keep it low going forward.
These topics will be covered
- Reducing license cost by finding and fixing misconfigurations and superfluous accounts
- How do CCB and CCX licenses really work?
- Understanding the DLAU tool and how to best utilize it
- Tips for common problem areas, like team mailboxes, functional/test users, etc
- Practical examples and best practices to implement right away
“An Outlook of the Ongoing and Future Relationship between Blockchain Technologies and Process-aware Information Systems.” Invited talk at the joint workshop on Blockchain for Information Systems (BC4IS) and Blockchain for Trusted Data Sharing (B4TDS), co-located with with the 36th International Conference on Advanced Information Systems Engineering (CAiSE), 3 June 2024, Limassol, Cyprus.
Climate Impact of Software Testing at Nordic Testing DaysKari Kakkonen
My slides at Nordic Testing Days 6.6.2024
Climate impact / sustainability of software testing discussed on the talk. ICT and testing must carry their part of global responsibility to help with the climat warming. We can minimize the carbon footprint but we can also have a carbon handprint, a positive impact on the climate. Quality characteristics can be added with sustainability, and then measured continuously. Test environments can be used less, and in smaller scale and on demand. Test techniques can be used in optimizing or minimizing number of tests. Test automation can be used to speed up testing.
Infrastructure Challenges in Scaling RAG with Custom AI modelsZilliz
Building Retrieval-Augmented Generation (RAG) systems with open-source and custom AI models is a complex task. This talk explores the challenges in productionizing RAG systems, including retrieval performance, response synthesis, and evaluation. We’ll discuss how to leverage open-source models like text embeddings, language models, and custom fine-tuned models to enhance RAG performance. Additionally, we’ll cover how BentoML can help orchestrate and scale these AI components efficiently, ensuring seamless deployment and management of RAG systems in the cloud.
OpenID AuthZEN Interop Read Out - AuthorizationDavid Brossard
During Identiverse 2024 and EIC 2024, members of the OpenID AuthZEN WG got together and demoed their authorization endpoints conforming to the AuthZEN API
AI-Powered Food Delivery Transforming App Development in Saudi Arabia.pdfTechgropse Pvt.Ltd.
In this blog post, we'll delve into the intersection of AI and app development in Saudi Arabia, focusing on the food delivery sector. We'll explore how AI is revolutionizing the way Saudi consumers order food, how restaurants manage their operations, and how delivery partners navigate the bustling streets of cities like Riyadh, Jeddah, and Dammam. Through real-world case studies, we'll showcase how leading Saudi food delivery apps are leveraging AI to redefine convenience, personalization, and efficiency.
For the full video of this presentation, please visit: https://www.edge-ai-vision.com/2024/06/building-and-scaling-ai-applications-with-the-nx-ai-manager-a-presentation-from-network-optix/
Robin van Emden, Senior Director of Data Science at Network Optix, presents the “Building and Scaling AI Applications with the Nx AI Manager,” tutorial at the May 2024 Embedded Vision Summit.
In this presentation, van Emden covers the basics of scaling edge AI solutions using the Nx tool kit. He emphasizes the process of developing AI models and deploying them globally. He also showcases the conversion of AI models and the creation of effective edge AI pipelines, with a focus on pre-processing, model conversion, selecting the appropriate inference engine for the target hardware and post-processing.
van Emden shows how Nx can simplify the developer’s life and facilitate a rapid transition from concept to production-ready applications.He provides valuable insights into developing scalable and efficient edge AI solutions, with a strong focus on practical implementation.
Programming Foundation Models with DSPy - Meetup SlidesZilliz
Prompting language models is hard, while programming language models is easy. In this talk, I will discuss the state-of-the-art framework DSPy for programming foundation models with its powerful optimizers and runtime constraint system.
Essentials of Automations: The Art of Triggers and Actions in FMESafe Software
In this second installment of our Essentials of Automations webinar series, we’ll explore the landscape of triggers and actions, guiding you through the nuances of authoring and adapting workspaces for seamless automations. Gain an understanding of the full spectrum of triggers and actions available in FME, empowering you to enhance your workspaces for efficient automation.
We’ll kick things off by showcasing the most commonly used event-based triggers, introducing you to various automation workflows like manual triggers, schedules, directory watchers, and more. Plus, see how these elements play out in real scenarios.
Whether you’re tweaking your current setup or building from the ground up, this session will arm you with the tools and insights needed to transform your FME usage into a powerhouse of productivity. Join us to discover effective strategies that simplify complex processes, enhancing your productivity and transforming your data management practices with FME. Let’s turn complexity into clarity and make your workspaces work wonders!
Removing Uninteresting Bytes in Software FuzzingAftab Hussain
Imagine a world where software fuzzing, the process of mutating bytes in test seeds to uncover hidden and erroneous program behaviors, becomes faster and more effective. A lot depends on the initial seeds, which can significantly dictate the trajectory of a fuzzing campaign, particularly in terms of how long it takes to uncover interesting behaviour in your code. We introduce DIAR, a technique designed to speedup fuzzing campaigns by pinpointing and eliminating those uninteresting bytes in the seeds. Picture this: instead of wasting valuable resources on meaningless mutations in large, bloated seeds, DIAR removes the unnecessary bytes, streamlining the entire process.
In this work, we equipped AFL, a popular fuzzer, with DIAR and examined two critical Linux libraries -- Libxml's xmllint, a tool for parsing xml documents, and Binutil's readelf, an essential debugging and security analysis command-line tool used to display detailed information about ELF (Executable and Linkable Format). Our preliminary results show that AFL+DIAR does not only discover new paths more quickly but also achieves higher coverage overall. This work thus showcases how starting with lean and optimized seeds can lead to faster, more comprehensive fuzzing campaigns -- and DIAR helps you find such seeds.
- These are slides of the talk given at IEEE International Conference on Software Testing Verification and Validation Workshop, ICSTW 2022.
GraphRAG for Life Science to increase LLM accuracyTomaz Bratanic
GraphRAG for life science domain, where you retriever information from biomedical knowledge graphs using LLMs to increase the accuracy and performance of generated answers
CAKE: Sharing Slices of Confidential Data on BlockchainClaudio Di Ciccio
Presented at the CAiSE 2024 Forum, Intelligent Information Systems, June 6th, Limassol, Cyprus.
Synopsis: Cooperative information systems typically involve various entities in a collaborative process within a distributed environment. Blockchain technology offers a mechanism for automating such processes, even when only partial trust exists among participants. The data stored on the blockchain is replicated across all nodes in the network, ensuring accessibility to all participants. While this aspect facilitates traceability, integrity, and persistence, it poses challenges for adopting public blockchains in enterprise settings due to confidentiality issues. In this paper, we present a software tool named Control Access via Key Encryption (CAKE), designed to ensure data confidentiality in scenarios involving public blockchains. After outlining its core components and functionalities, we showcase the application of CAKE in the context of a real-world cyber-security project within the logistics domain.
Paper: https://doi.org/10.1007/978-3-031-61000-4_16
CAKE: Sharing Slices of Confidential Data on Blockchain
International Biobanking: Oportunities and Challenges for Private-Public Collaboration
1.
2.
3. Biobanks and the Pharmaceutical Industry Disease as opposed to population focus Clinical trial-related translational research Valuable information regarding treatment outcomes Private
4.
5.
6.
7. The SNP Consortium International HapMap Project Genotyping Chips Adapted from David Altshuler, Harvard Medical School, 2007
8.
9.
10. The Public Has Mixed Feelings Regarding Genetic Research
11. NCAA's sickle cell test plan raises fears Erin Allday, Chronicle Staff Writer Monday, September 14, 2009 A recent NCAA recommendation to screen college athletes for sickle cell trait - the gene that can cause sickle cell disease - is raising the hackles of some experts who say testing is probably unnecessary, and may even lead to inadvertent discrimination against minority players. Sickle cell disease is a blood disorder that can cause severe pain, stroke and death, but sickle cell trait is almost always benign, and many people never know whether they carry the gene. About 8 percent of black people and about 1 percent of Latinos have sickle cell trait, but it's rare among white people, affecting only about 1 in 10,000. The United States has a long history of discrimination against people with sickle cell trait, said Troy Duster, a sociologist at UC Berkeley and New York University. In the 1960s, people who tested positive weren't allowed into the Air Force Academy, and into the '70s people were denied insurance or certain jobs, he said. It's irresponsible to screen people when there's little scientific evidence that the gene causes death and no specific precautions athletes can take to protect themselves, Duster said. "When you screen someone, the question is, for what? What are you going to do with that information?" Duster said. "The NCAA is saying they want education, but education requires research, and there's no research."